Cytrellis to Present at Canaccord Genuity CG MedTech Diagnostics and Digital Health & Services Forum

WOBURN, Mass., Nov. 15, 2023 /PRNewswire/ -- Cytrellis Biosystems, a pioneer in novel medical aesthetic solutions and manufacturer of ellacor^® and its proprietary Micro-Coring^® Technology, today announced members of the Cytrellis leadership team will participate at the Canaccord Genuity CG MedTech Diagnostics and Digital Health & Services Forum.

Presenters: Jason Richey, President & Chief Executive Officer and Jackson McAdam, Chief Financial Officer
Format: In-person presentation, fireside chat, and one-on-one meetings
Location: New York, NY
When: November 16, 2023

About ellacor^®
The ellacor^® system with Micro-Coring^® technology is the first-and-only non-surgical procedure to remove sagging skin on the micro-scale. This pioneering system targets moderate and severe wrinkles in the mid and lower face, setting new standards in skin revitalization. Utilizing the groundbreaking, patented Micro-Coring^® technology, the ellacor^® system precisely removes full thickness cores of dermal and epidermal tissue with a 22 gauge (410 microns) hollow needle without thermal energy. The needle's minimal diameter minimizes any potential scarring risk, prioritizing patient safety and satisfaction. Indicated for use by qualified medical professionals, the ellacor^® system with Micro-Coring^® technology is designed for adults aged 22 years or older, encompassing Fitzpatrick skin types I-IV. For more information visit ellacor.com.

About Cytrellis Biosystems
Cytrellis is a medical technology company dedicated to the development and commercialization of first-in-class aesthetic devices. Cytrellis' first product, ellacor^® system with Micro-Coring technology, is a novel, proprietary system that removes sagging skin to address moderate and severe wrinkles. Ellacor^® provides aesthetic practitioners with an unprecedented ability to improve age-related changes in skin to help restore youthful beauty.

Contacts: 
Media: EvolveMKD – [email protected]
Investor Relations: Jackson McAdam, Chief Financial Officer [email protected]

SOURCE Cytrellis